STOCK TITAN

Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Gilead Sciences: Research Scholars Program Supports Early-Career Investigators Focused on Advancing Scientific Knowledge in HIV Research, Fueling HIV Research Through the Program, Addressing Unmet Needs in HIV Research
Positive
  • The Research Scholars Program supports early-career investigators in advancing scientific knowledge in HIV research, reducing barriers to entry for underrepresented applicants, and encouraging collaborative research approaches globally.
  • The program is crucial for many early-career HIV investigators, providing funding to explore innovative ideas and establish careers.
  • The program strives to meet unmet needs in HIV research, such as addressing health inequities and improving physical function for people with HIV as they age.
Negative
  • None.

NORTHAMPTON, MA / ACCESSWIRE / November 9, 2023 / Gilead Sciences / Dr. Shringar Rao's inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs. Even as an early-career researcher, she has a distinct and ambitious mission - to not lose anyone to a preventable HIV-related death - and is working with numerous other researchers in support of this goal.

"If we really want to make a difference, then we need to collaborate with people all over the world," says Shringar, a virologist at Erasmus University Medical Center in Rotterdam, Netherlands, who's trying to develop interventions that can eliminate latent HIV in populations worldwide. "As a scientist, this involves engaging with diverse communities."

Shringar is one of 50 early-career investigators supported through Gilead's Research Scholars Program (RSP) who are focused on advancing scientific knowledge in areas of unmet medical need for people affected by HIV. This year marks nearly a decade since the launch of the program, which funds junior researchers in a variety of areas and works to reduce barriers to entry for underrepresented applicants. The RSP also continues to facilitate connections between scholars globally to encourage collaborative research approaches in the effort to help end the HIV epidemic for everyone, everywhere.

Fueling HIV Research Through the Research Scholars Program
For many early-career HIV investigators, funding from the RSP comes at a crucial point in their research journey. With the support, the scholars can explore ideas outside of the box and potentially further establish ideas that might not typically receive funding, laying the foundation for their careers.

"The Research Scholars Program is important and beneficial to junior faculty because it opens doors that they may not be able to enter otherwise," explains Dr. Gaea Daniel, a 2021 RSP award recipient whose work focuses on HIV prevention research and strategies to advance health equity in support of Black women.

Addressing Unmet Needs in HIV Research
Dr. Kristine Erlandson, an infectious disease clinician and researcher at the University of Colorado Anschutz Medical Campus, says her research area is under-resourced. However, as an RSP investigator in 2015, she has been able to explore innovative intervention and clinical care models to improve the physical function of people with HIV as they age.

"The long-term success of my research would mean that people with HIV can experience life to the fullest," says Kristine. "The Research Scholars Program really strives to help meet unmet needs in research."

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View source version on accesswire.com:
https://www.accesswire.com/801651/gilead-sciences-research-scholars-program-scientists-advancing-hiv-research

The Research Scholars Program supports early-career investigators focused on advancing scientific knowledge in HIV research.

The program funds junior researchers in areas of unmet medical need for people affected by HIV and reduces barriers to entry for underrepresented applicants.

The program aims to encourage collaborative research approaches globally and meet unmet needs in HIV research, such as addressing health inequities and improving physical function for people with HIV as they age.
Gilead Sciences, Inc.

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.